Compliance
This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.
The drug company Eli Lilly on Monday announced that it is introducing a cheaper version of its insulin that will sell at half the price, a decision aimed at tamping down the outcry over insulin prices.
A woman received nearly $375,000 from her insurance company over several months for treatment she received at a California rehabilitation facility. A man received more than $130,000 after he sent his fiancée's daughter for substance abuse treatment.
The Blue Cross and Blue Shield Association wants to resurrect congressional efforts to stabilize the Affordable Care Act's exchanges by boosting tax subsidies and cost-sharing payments.
As much as payers are hoping to expand the acceptance of using value-based insurance design (VBID), consumers are still distrustful of what insurance companies deem as high-quality services.
House Democrats will begin considering legislation to lower drug prices at a hearing next week, moving forward on one of their top priorities, according to people familiar with the plan.
The sweeping health-care law created nearly a decade ago to put insurance within reach of more Americans has left significant holes in the ability of older, middle-class people to afford coverage, particularly in rural areas, according to a new analysis.
Aon Plc is considering an offer to buy rival insurance brokerage Willis Towers Watson Plc, according to people familiar with the matter, in what could be the industry’s largest ever merger.
Medicare For All is choice for none, a health care expert told members of the National Association of Health Underwriters at their Capitol Conference today.
Both insurers and healthcare organizations are against the Medical For All Act introduced by House Democrats this week.
A line of defense is emerging for top prescription drug companies whose topexecutives will be pulled before Congress on Tuesday to testify about high prices for medicine: They are not to blame.